nach oben

European Journal of Clinical Microbiology & Infectious Diseases

Erschienen in:

08.01.2022 | Original Article

Household transmission of SARS-CoV-2 infection in the Paris/Ile-de-France area

verfasst von: Christine Katlama, Yasmine Dudoit, Julien Huyard, Christine Blanc, Cathia Soulié, Luminita Schneider, Antoine Faycal, Ludovic Lenclume, Naima Hamani, Naoual Qatib, Roland Tubiana, Sophie Seang, Baptiste Sellem, Dominique Costagliola, Romain Palich, Marc-Antoine Valantin, Lambert Assoumou

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

This st udy aims to evaluate the prevalence of SARS-CoV-2 antibodies in locked-down family households to determine viral dynamics and immunity acquisition. COVID-19 individuals and their households in lockdown under the same roof during early spring 2020 were interviewed and tested using rapid immunochromatographic lateral flow antibodies assays (LFA) between July and September 2020. Outcomes were secondary infection rate (SIR) among contacts, household infection rate, and predictors of transmission. We enrolled 87 households including 87 COVID-19 index cases (female 78.2%; median age: 47.0 years, IQR: 42.0–51.5) and 255 contacts (males: 52.9%; median age: 19.0 years, IQR: 11.0–43.5) consisting of their children (42%) or spouses/partners (28.2%). A total of 95/255 contacts were SARS-CoV-2 antibody positive leading to a SIR of 37.3% (95% confidence interval (CI): 31.3–43.5%). Viral transmission was observed in 54 households (62%). SARS-CoV-2 infection was asymptomatic in 33/95 (34.7%) of SARS-CoV-2-positive contacts. Independent predictors of virus transmission from index to contacts were housing surface area < 60 m² (OR: 5.6 [1.1; 28.2] and a four-member family compared to five (OR: 3.6 [1.2; 10.3]). Households represent a high-risk setting for SARS-CoV-2 transmission through close contact within the family amplified by the number of family members and the housing surface area.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5CrossRefPubMedPubMedCentral

Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med NEJMoa2002032. https://doi.org/10.1056/NEJMoa2002032

Long Q-X, Tang X-J, Shi Q-L, Li Q, Deng H-J, Yuan J et al (2020) Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 26(8):1200–4. https://doi.org/10.1038/s41591-020-0965-6CrossRefPubMed

Meyerowitz EA, Richterman A, Gandhi RT, Sax PE (2020) Transmission of SARS-CoV-2: a review of viral, host, and environmental factors. Ann Intern Med. https://doi.org/10.7326/M20-5008CrossRefPubMedPubMedCentral

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y et al (2020) Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 382(13):1199–207. https://doi.org/10.1056/NEJMoa2001316CrossRefPubMedPubMedCentral

Qian H, Miao T, Liu L, Zheng X, Luo D, Li Y (2020) Indoor transmission of SARS-CoV-2. MedRxiv 2020.04.04.20053058. https://doi.org/10.1101/2020.04.04.20053058

Madewell ZJ, Yang Y, Longini IM, Halloran ME, Dean NE (2020) Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate. MedRxiv 2020.07.29.20164590. https://doi.org/10.1101/2020.07.29.20164590

Fung HF, Martinez L, Alarid-Escudero F, Salomon JA, Studdert DM, Andrews JR et al (2020) The household secondary attack rate of SARS-CoV-2: a rapid review. Clin Infect Dis. https://doi.org/10.1093/cid/ciaa1558CrossRefPubMedPubMedCentral

Luo L, Liu D, Liao X, Wu X, Jing Q, Zheng J et al (2020) Contact settings and risk for transmission in 3410 close contacts of patients with COVID-19 in Guangzhou, China : a prospective cohort study. Ann Intern Med 173(11):879–87. https://doi.org/10.7326/M20-2671CrossRefPubMed

10.

Ng OT, Marimuthu K, Koh V, Pang J, Linn KZ, Sun J et al (2020) SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study. Lancet Infect Dis. https://doi.org/10.1016/S1473-3099(20)30833-1CrossRefPubMedPubMedCentral

11.

Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z et al (2020) Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. Lancet Infect Dis. https://doi.org/10.1016/S1473-3099(20)30287-5CrossRefPubMedPubMedCentral

12.

Jing Q-L, Liu M-J, Yuan J, Zhang Z-B, Zhang A-R, Dean NE et al (2020) Household secondary attack rate of COVID-19 and associated determinants. MedRxiv. https://doi.org/10.1101/2020.04.11.20056010CrossRefPubMedPubMedCentral

13.

Li W, Zhang B, Lu J, Liu S, Chang Z, Cao P et al (2020) The characteristics of household transmission of COVID-19. Clin Infect Dis. https://doi.org/10.1093/cid/ciaa450CrossRefPubMedPubMedCentral

14.

He X, Lau EHY, Wu P, Deng X, Wang J, Hao X et al (2020) Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med 1–4. https://doi.org/10.1038/s41591-020-0869-5

15.

To KK-W, Tsang Owen T-Yi, Leung W-S, Tam AR, Wu T-C, Lung DC et al (2020) Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis 0(0). https://doi.org/10.1016/S1473-3099(20)30196-1

16.

Estimating the burden of SARS-CoV-2 in France - PubMed. Available at https://pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/32404476/. Accessed January 11, 2021, n.d.

17.

Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK et al (2020) Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 25(3). https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045

18.

Prazuck T, Colin M, Giachè S, Gubavu C, Seve A, Rzepecki V et al (2020) Evaluation of performance of two SARS-CoV-2 rapid IgM-IgG combined antibody tests on capillary whole blood samples from the fingertip. PLoS One 15(9):e0237694CrossRefPubMedPubMedCentral

19.

Wilkinson K, Chen X, Shaw S (2020) Secondary attack rate of COVID-19 in household contacts in the Winnipeg Health Region, Canada. Can J Public Health 1–5. https://doi.org/10.17269/s41997-020-00451-x

20.

Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F et al (2020) Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis. https://doi.org/10.1093/cid/ciaa310CrossRefPubMedPubMedCentral

21.

Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y et al (2020) Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. https://doi.org/10.1093/cid/ciaa344CrossRefPubMedPubMedCentral

22.

Lee Y-L, Liao C-H, Liu P-Y, Cheng C-Y, Chung M-Y, Liu C-E et al (2020) Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 patients. J Infect. https://doi.org/10.1016/j.jinf.2020.04.019CrossRefPubMedPubMedCentral

23.

Lewis NM, Chu VT, Ye D, Conners EE, Gharpure R, Laws RL et al (2020) Household transmission of SARS-CoV-2 in the United States. Clin Infect Dis. https://doi.org/10.1093/cid/ciaa1166CrossRefPubMedPubMedCentral

24.

Rosenberg ES, Dufort EM, Blog DS, Hall EW, Hoefer D, Backenson BP et al (2020) COVID-19 testing, epidemic features, hospital outcomes, and household prevalence, New York State-March 2020. Clin Infect Dis 71(8):1953–9. https://doi.org/10.1093/cid/ciaa549CrossRefPubMed

25.

Brotons P, Launes C, Buetas E, Fumado V, Henares D, de Sevilla MF et al (2020) Susceptibility to SARS-CoV-2 infection among children and adults: a seroprevalence study of family households in the Barcelona Metropolitan Region. Spain Clin Infect Dis. https://doi.org/10.1093/cid/ciaa1721CrossRef

26.

O Murchu E, Byrne P, Walsh KA, Carty PG, Connolly M, De Gascun C et al (2020) Immune response following infection with SARS-CoV-2 and other coronaviruses: a rapid review. Rev Med Virol e2162. https://doi.org/10.1002/rmv.2162

27.

Tagarro A, Epalza C, Santos M, Sanz-Santaeufemia FJ, Otheo E, Moraleda C et al (2020) Screening and severity of coronavirus disease 2019 (COVID-19) in children in Madrid, Spain. JAMA Pediatr. https://doi.org/10.1001/jamapediatrics.2020.1346CrossRefPubMedPubMedCentral

28.

Zhongliang W, Wanli Ma, ZhengXin Wu, Gang ZR (2020) Household transmission of SARS-CoV-2. J Infect. https://doi.org/10.1016/j.jinf.2020.03.040CrossRef

29.

Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ (2020) Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet 395(10242):1973–87. https://doi.org/10.1016/S0140-6736(20)31142-9CrossRefPubMedPubMedCentral

30.

Kampf G, Brüggemann Y, Kaba HEJ, Steinmann J, Pfaender S, Scheithauer S et al (2020) Potential sources, modes of transmission and effectiveness of prevention measures against SARS-CoV-2. J Hosp Infect 106(4):678–697. https://doi.org/10.1016/j.jhin.2020.09.022CrossRefPubMedPubMedCentral

31.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G et al (200) A trial of lopinavir–ritonavir in adults hospitalized with severe COVID-19. N Engl J Med NEJMoa2001282. https://doi.org/10.1056/NEJMoa2001282

32.

Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y et al (2020) Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395(10236):1569–78. https://doi.org/10.1016/S0140-6736(20)31022-9CrossRefPubMedPubMedCentral

33.

Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R et al (2020) Remdesivir for 5 or 10 days in patients with severe COVID-19. N Engl J Med 383(19):1827–37. https://doi.org/10.1056/NEJMoa2015301CrossRefPubMed

34.

Coronavirus Disease 2019 (COVID-19) (n.d.) Information for NIH applicants and recipients of NIH funding | grants.nih.gov. Available at https://grants.nih.gov/policy/natural-disasters/corona-virus.htm. Accessed January 28, 2021

35.

Cox RM, Wolf JD, Plemper RK (2020) Therapeutic MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Res Sq. https://doi.org/10.21203/rs.3.rs-89433/v1CrossRefPubMedPubMedCentral

36.

Rosenke K, Hansen F, Schwarz B, Feldmann F, Haddock E, Rosenke R et al (2020) Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model. Res Sq. https://doi.org/10.21203/rs.3.rs-86289/v1CrossRefPubMedPubMedCentral

37.

Ridgeback Biotherapeutics LP (2021) A phase IIa randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of EIDD-2801 to eliminate infectious virus detection in persons with COVID-19. clinicaltrials.gov

38.

Ridgeback Biotherapeutics LP (2021) The safety of EIDD-2801 and its effect on viral shedding of SARS-CoV-2. clinicaltrials.gov

39.

Anderson EJ, Rouphael NG, Widge AT, Jackson A, Roberts PC, Makhene M et al (2020) Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 383(25):2427–38. https://doi.org/10.1056/NEJMoa2028436CrossRefPubMed

40.

Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A et al (2020) Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates. N Engl J Med 383(25):2439–50. https://doi.org/10.1056/NEJMoa2027906CrossRefPubMed

41.

Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK et al (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397(10269):99–111. https://doi.org/10.1016/S0140-6736(20)32661-1CrossRefPubMedPubMedCentral

Titel: Household transmission of SARS-CoV-2 infection in the Paris/Ile-de-France area
verfasst von: Christine Katlama
Yasmine Dudoit
Julien Huyard
Christine Blanc
Cathia Soulié
Luminita Schneider
Antoine Faycal
Ludovic Lenclume
Naima Hamani
Naoual Qatib
Roland Tubiana
Sophie Seang
Baptiste Sellem
Dominique Costagliola
Romain Palich
Marc-Antoine Valantin
Lambert Assoumou
Publikationsdatum: 08.01.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 3/2022
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-021-04345-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Household transmission of SARS-CoV-2 infection in the Paris/Ile-de-France area

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2022

Emergence of Mycobacterium canariasense infections in central Israel

Correction to: Rapid molecular detection of pathogenic microorganisms and antimicrobial resistance markers in blood cultures: evaluation and utility of the next-generation FilmArray Blood Culture Identification 2 panel

False-positive immunochromatographic CTX-M enzyme test from direct testing of a positive blood culture

Impact of FilmArray™ Respiratory Panel testing on the clinical management of pediatric bone marrow transplant patients

Antimicrobial activities of aztreonam-avibactam and comparator agents tested against Enterobacterales from European hospitals analysed by geographic region and infection type (2019–2020)

Acute kidney injury in Staphylococcus aureus bacteremia

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin